- Home
- CTMX vs ZTR Comparison
CTMX vs ZTR Comparison
Compare CTMX & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ZTR
- Stock Information
- Founded
- CTMX 2008
- ZTR 1988
- Country
- CTMX United States
- ZTR Australia
- Employees
- CTMX N/A
- ZTR N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ZTR Investment Managers
- Sector
- CTMX Health Care
- ZTR Finance
- Exchange
- CTMX Nasdaq
- ZTR Nasdaq
- Market Cap
- CTMX 378.1M
- ZTR 338.8M
- IPO Year
- CTMX 2015
- ZTR N/A
- Fundamental
- Price
- CTMX $2.64
- ZTR $6.17
- Analyst Decision
- CTMX Strong Buy
- ZTR
- Analyst Count
- CTMX 2
- ZTR 0
- Target Price
- CTMX $5.00
- ZTR N/A
- AVG Volume (30 Days)
- CTMX 11.3M
- ZTR 219.4K
- Earning Date
- CTMX 05-12-2025
- ZTR 01-01-0001
- Dividend Yield
- CTMX N/A
- ZTR 12.09%
- EPS Growth
- CTMX 128.27
- ZTR N/A
- EPS
- CTMX 0.49
- ZTR N/A
- Revenue
- CTMX $147,557,000.00
- ZTR N/A
- Revenue This Year
- CTMX N/A
- ZTR N/A
- Revenue Next Year
- CTMX N/A
- ZTR N/A
- P/E Ratio
- CTMX $5.44
- ZTR N/A
- Revenue Growth
- CTMX 23.81
- ZTR N/A
- 52 Week Low
- CTMX $0.40
- ZTR $4.50
- 52 Week High
- CTMX $2.82
- ZTR $6.60
- Technical
- Relative Strength Index (RSI)
- CTMX 67.47
- ZTR 58.32
- Support Level
- CTMX $2.35
- ZTR $6.14
- Resistance Level
- CTMX $2.75
- ZTR $6.23
- Average True Range (ATR)
- CTMX 0.25
- ZTR 0.07
- MACD
- CTMX -0.01
- ZTR -0.00
- Stochastic Oscillator
- CTMX 78.82
- ZTR 70.00
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.